Please login to the form below

Not currently logged in
Email:
Password:

Strategy

This page shows the latest Strategy news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

FDA adcomm split on Sanofi’s type 1 diabetes drug

Some of the panellists who voted in favour of Zynquista did so on the premise that the FDA would ask for a risk evaluation and mitigation strategy (REMS) to try to

Latest news

More from news
Approximately 112 fully matching, plus 2,688 partially matching documents found.

Latest Intelligence

  • Launch excellence: beyond the six-month mantra Launch excellence: beyond the six-month mantra

    authorisation. With the initial emphasis on strategy, teams then transition towards implementation and organisational engagement as launch approaches. ... Post-launch, teams should revisit their assumptions and assess if their strategy is correct, if

  • Escaping the spin cycle of sub-optimal launch Escaping the spin cycle of sub-optimal launch

    Rapid learning and the agile incorporation of new insight into brand strategy is essential. ... We still see companies developing brand strategies that 'target' all patients and all physicians – but that is simply not focused!

  • Launch like a PRO: the art and science of successful entry to market Launch like a PRO: the art and science of successful entry to market

    From strategy to project management, market access to public affairs, governance to HEOR, they provide an incredibly thorough test of an organisation’s capability. ... 2. Organisation: core team for strategy, alignment and driving the plan, sub-teams

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    In 2019, every early innovator’s launch plan needs to include strategies and associated accountabilities for proactive exit planning. ... Those exits can include true acquisition strategies as well as strategic outsourcing and partnerships.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    There are a variety of strategies attempting to overcome intrinsic resistance to a PD-1/PD-L1 blockade, [and] the rationale for any individual combination is usually based on the proposed ... This has shaped industry development strategies, said Stefan

More from intelligence
Approximately 42 fully matching, plus 446 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 492 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 96 fully matching, plus 537 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics